REGN:NASDAQ
Regeneron Pharmaceuticals Inc
$774.11
arrow_downward
-2.47%(-19.63) 1D
$774.11
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 15, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for REGN...
Open
$788.53
High
$788.58
Low
$769.57
Mkt. cap
79.70B
Avg. vol.
675.80K
Volume
540.56K
Dividend
0.49%
Quarterly dividend
$0.94
Ex-dividend date
Aug 18, 2026
P/E ratio
19.14
52-wk high
$859.34
52-wk low
$541.00
EPS
$40.45
Beta
0.20
Shares outstanding
101.14M
No. of employees
15K
Open
$788.53
High
$788.58
Low
$769.57
Mkt. cap
79.70B
Avg. vol.
675.80K
Volume
540.56K
Dividend
0.49%
Quarterly dividend
$0.94
Ex-dividend date
Aug 18, 2026
P/E ratio
19.14
52-wk high
$859.34
52-wk low
$541.00
EPS
$40.45
Beta
0.20
Shares outstanding
101.14M
No. of employees
15K
News stories
From web sources and news partners
News Corp
·
54 minutes ago
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
Simply Wall Street
·
2 hours ago
Is Regeneron Pharmaceuticals (REGN) Still Undervalued After The Class Action Lawsuits?
ad-hoc-news.de
·
5 hours ago
Regeneron stock gains as Dupixent and Cemdisiran drive growth and Q2 results impress
The Motley Fool
·
7 hours ago
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Profile
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. Wikipedia
About Regeneron Pharmaceuticals Inc
CEOLeonard Schleifer
Employees15.3K
Founded1988
HeadquartersTarrytown, New York, United States
SectorBiotechnology
Websiteregeneron.com